Bringing Better Health Within Reach: Hikma’s journey to become the Partner of choice in MENA
London, 29 April 2024 – When Hikma was founded in 1978, its central purpose was to fill a profound gap in access to high-quality affordable medicines across the Middle East and North Africa (MENA) region. While the scope and reach of Hikma’s operations has expanded since then, improving patients’ access to health remains our central purpose nearly 50 years later.
2023 was an exceptional year for Hikma in which we became the second largest pharmaceutical company in the MENA region by sales1 . We significantly expanded the availability of essential treatments in the region and grew our extensive network of global partners through strategic partnerships, including with Guardant Health, Rakuten Medical, SK Biopharmaceuticals, Celltrion, Junshi and Cosmo.
Our MENA business development team had a record year in deal signing - adding more than 25 assets to our portfolio through strategic partnerships. These partnerships brought innovative interventions for cancer, autoimmune diseases, and CNS amongst other conditions to MENA - fundamentally improving access to world-class diagnostics and treatments and ultimately the quality of life of patients in the region. We have firmly positioned ourselves as a partner of choice for multinational companies aligned with our vision of shaping a healthier world and looking to expand access to new technologies and health innovations in the region.
This is made possible by Hikma’s unparalleled access, deep understanding, and connectivity with health communities in each country where we operate. As we continue to enhance our leading position in MENA, we remain focused on our duty and responsibility to bring new treatments, access and innovative solutions into the region. Our scale, breadth of offering, strong commercial capabilities, and our deep-rooted ties to MENA help us deliver on our goal of putting better health within reach for patients across the region.
Over the coming weeks, we will explore in a series of posts how we are evolving our business as the partner of choice for international companies that cover wider healthcare solutions who are looking to expand in MENA – a region with high unmet needs and wealth of opportunities.
1 Based on internal analysis by Hikma using IQVIA MIDAS® Monthly value sales data for Kuwait, KSA, UAE, Jordan, Lebanon, Egypt, Tunisia, Algeria and Morocco, MAT Dec 2023, reflecting estimates of real-world activity. Copyright IQVIA. All rights reserved.